 |
|
Use of Sympathomimetic Drugs Leads to Increased Risk of Hospitalization for Arrhythmias in Patients With Congestive Heart Failure
Marcel L. Bouvy, PharmD;
Eibert R. Heerdink, PhD;
Marie L. De Bruin, PharmD;
Ron M. C. Herings, PhD;
Hubert G. M. Leufkens, PhD;
Arno W. Hoes, PhD
Arch Intern Med. 2000;160:2477-2480.
Background Sympathomimetic agents have a direct positive chronotropic effect on heart rate and may cause hypokalemia, even when administered by inhalation. In selected patients (eg, patients with congestive heart failure [CHF]) this can lead to arrhythmias. Despite the potential adverse effects of these agents, they are used frequently in patients with CHF, due to a high incidence of respiratory comorbidity. This study investigates the effects of sympathomimetics on the incidence of hospitalizations for arrhythmias in patients with CHF.
Methods In a cohort of 1208 patients with a validated hospital discharge diagnosis of CHF, we identified 149 cases with a readmission for arrhythmias, and compared these in a nested matched case-control design with 149 controls from the remainder of the cohort with no hospital readmission for any cardiac cause. Conditional logistic regression was used to calculate the risk for hospitalization for arrhythmias associated with exposure to sympathomimetic agents, expressed as odds ratios.
Results Of 149 case patients, a total of 33 (22.1%) were treated with any sympathomimetic agent, and 6 patients (4.0%) were treated with systemic sympathomimetics. The use of any sympathomimetic drug was associated with an increased risk of admission for arrhythmia (odds ratio, 4.0; 95% confidence interval, 1.0-15.1). For systemic sympathomimetic drugs, the corresponding odds ratio was 15.7 (95% confidence interval, 1.1-228.0).
Conclusions The results of this study strongly suggest an increased risk of hospitalization for arrhythmias in patients with CHF treated with sympathomimetic drugs. Sympathomimetics should be given under close surveillance to patients with CHF.
From the Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht (Drs Bouvy, Heerdink, De Bruin, Herings, and Leufkens), Stevenshof Institute for Research, Leiden (Dr Bouvy), and Julius Centre for Patient-Oriented Research, Utrecht (Dr Hoes), the Netherlands.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(16):2551-2552.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy: Results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM)
Greenberg et al.
Circulation 2008;118:1241-1249.
ABSTRACT
| FULL TEXT
Continuous Aortic Flow Augmentation: A Pilot Study of Hemodynamic and Renal Responses to a Novel Percutaneous Intervention in Decompensated Heart Failure
Konstam et al.
Circulation 2005;112:3107-3114.
ABSTRACT
| FULL TEXT
Predicting Cardiac Arrhythmias and Sudden Death in Diabetic Users of Proarrhythmic Drugs
De Bruin et al.
Diabetes Care 2005;28:440-442.
FULL TEXT
Keeping Your Patient With Heart Failure Safe: A Review of Potentially Dangerous Medications
Amabile and Spencer
Arch Intern Med 2004;164:709-720.
FULL TEXT
Autonomic Tone as a Cardiovascular Risk Factor: The Dangers of Chronic Fight or Flight
Curtis and O'Keefe
Mayo Clin Proc. 2002;77:45-54.
ABSTRACT
Baseline Rates of Disease May Account for Some Arrhythmia Risk
Williams et al.
Arch Intern Med 2001;161:1235-1236.
FULL TEXT
|
